T6276

NU7441 (KU-57788 (NU7441)) is a highly effective and specific DNA-PK inhibitor (IC50: 14 nM).

ROMK-IN-32 is an inhibitor of the extra-renal medullary potassium channel (ROMK) (IC50: 35 nM) and also inhibits hERG (IC50: 22 μM).

CB1 agonist 1 is a potent CB1 agonist with a pIC50 value of 5.7 for CB1 receptors.CB1 agonist 1 can be used to study brain disorders, pain, and inflammation.

RIPK1-IN-11 is an orally active RIPK1 inhibitor with a Kd value of 9.2 nM and an IC50 value of 67 nM. RIPK1-IN-11 inhibits necrosis in human and mouse cells and exhibits anti-inflammatory effects.

VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 with an IC50 of 0.037 μM and demonstrates anti-tumor effects.

Estrogen receptor α antagonist 1 (compound 35) is a highly selective antagonist of estrogen receptor α, demonstrating an IC50 of 0.02 μM against this receptor and also affecting estrogen receptor β. This compound is utilized in tumor research.

WRNA10 is a potent binding agent for HIV-1TAR RNA (IC50: 10 μM, CC50: 40 μM).

Mu opioid receptor antagonist 2 (compound 25) is a potent and selective mu opioid receptor (MOR) antagonist that permeates the blood-brain barrier (Ki: 0.37 nM, EC50: 0.44 nM), and can be used to study opioid use disorder (OUD).

Mu opioid receptor antagonist 3 (compound 26) is a potent and selective MOR antagonist with the ability to penetrate the blood-brain barrier (Ki: 0.24 nM, EC50: 0.54 nM). This compound can be used to study opioid use disorder (OUD).

Mu opioid receptor antagonist 4 (compound 31) is a potent and selective MOR antagonist that permeates the blood-brain barrier (Ki: 0.38 nM, EC50: 0.38 nM) and can be used to study opioid use disorder (OUD).

Tribendimidine is a broad-spectrum, orally active anthelmintic and an L-type nicotinic acetylcholine receptor (nAChR) agonist. tribendimidine is highly active against A. lumbricoides and N. americanus.